Equities analysts expect Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings of ($0.41) per share for the current quarter, according to Zacks. Four analysts have provided estimates for Dicerna Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.28 and the lowest estimate coming in at ($0.97). Dicerna Pharmaceuticals reported earnings per share of ($0.29) during the same quarter last year, which indicates a negative year-over-year growth rate of 41.4%. The company is expected to announce its next quarterly earnings results on Thursday, November 4th.
Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Monday, August 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of $0.51 by ($1.04). Dicerna Pharmaceuticals had a negative net margin of 72.28% and a negative return on equity of 97.72%.
Shares of NASDAQ:DRNA traded up $0.22 during trading on Friday, reaching $21.61. 2,182,931 shares of the stock were exchanged, compared to its average volume of 874,292. Dicerna Pharmaceuticals has a 12-month low of $17.76 and a 12-month high of $40.14. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -12.71 and a beta of 0.99. The firm’s 50-day moving average price is $27.54 and its 200 day moving average price is $29.26.
In other Dicerna Pharmaceuticals news, insider Ling Zeng sold 1,334 shares of the company’s stock in a transaction that occurred on Friday, September 17th. The stock was sold at an average price of $21.47, for a total value of $28,640.98. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Shreeram Aradhye sold 2,056 shares of the business’s stock in a transaction that occurred on Friday, September 17th. The shares were sold at an average price of $21.47, for a total value of $44,142.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,825 shares of company stock worth $1,965,394. 10.20% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. RTW Investments LP increased its holdings in shares of Dicerna Pharmaceuticals by 0.8% in the 2nd quarter. RTW Investments LP now owns 7,521,859 shares of the biopharmaceutical company’s stock valued at $280,716,000 after acquiring an additional 58,568 shares during the last quarter. BlackRock Inc. grew its stake in Dicerna Pharmaceuticals by 1.4% during the 1st quarter. BlackRock Inc. now owns 6,117,166 shares of the biopharmaceutical company’s stock worth $156,417,000 after buying an additional 82,437 shares during the last quarter. Vanguard Group Inc. grew its stake in Dicerna Pharmaceuticals by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,620,353 shares of the biopharmaceutical company’s stock worth $135,112,000 after buying an additional 52,708 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Dicerna Pharmaceuticals by 17.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,982,925 shares of the biopharmaceutical company’s stock worth $74,003,000 after buying an additional 289,743 shares during the last quarter. Finally, Woodline Partners LP grew its stake in Dicerna Pharmaceuticals by 30.8% during the 1st quarter. Woodline Partners LP now owns 1,777,000 shares of the biopharmaceutical company’s stock worth $45,438,000 after buying an additional 418,204 shares during the last quarter. Institutional investors and hedge funds own 78.44% of the company’s stock.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
See Also: How analysts view the yield curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.